Real World Evidence Solutions Market Size- By Component, By Application, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Description

Introduction and Overview

According to SPER Market Research, 'Global Real World Evidence Solutions Market Size- By Component, By Application, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Real World Evidence Solutions Market is predicted to reach USD 6.86 billion by 2033 with a CAGR of 15.43%.

Healthcare data obtained from non-traditional clinical research settings, such as electronic medical records (EMRs), claims and billing information, product and disease registries, and information obtained through mobile devices and health applications, is referred to as real-world evidence. Administrative/claims data, clinical data, patient-generated or reported data, and emerging data sources including as social media and cross-industry data collaborations such as Project Data Sphere are the four main sources of real-time data collecting.

The COVID-19 epidemic had a significant impact on the real-world evidence (RWE) business. On the one hand, it has emphasized the need of evaluating the success of treatments and interventions in a more immediate and practical environment utilizing real-world data. Because of the urgency of the pandemic, there is a heightened desire for immediate insights beyond usual clinical research.

Scope of the Report

Report Metric Details:

Market size available for years: 2019-2033

Base year considered: 2022

Forecast period: 2023-2033

Segments covered: By Component, By Application, By End User

Regions covered: North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

Companies Covered: IQVIA Holdings, IBM Corporation, OPTUM Inc, Icon Plc, Syneous Health Inc, Paraxel Health Inc, Paraxel International Corporation, Othres

Market Segmentation:

By Application: Based on the Application, Global Real World Evidence Solutions Market is segmented as; Drug Development and Approvals, Post-Market Surveillance, Market Access Reimbursement/Coverage Decision Making, Clinical and Regulatory Decision-Making.

By End User: Based on the End User, Global Real World Evidence Solutions Market is segmented as; Pharmaceutical & Medical Device Companies, Healthcare Providers, Healthcare Payers, Other

By Region: This report also provides the data for key regional segments of North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

Product Code: HLCA2356

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Real World Evidence Solutions Market

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Real World Evidence Solutions Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Real World Evidence Solutions Market

7. Global Real World Evidence Solutions Market, By Component (USD Million)

7.1. Global Real World Evidence Solutions Market Value Share and Forecast, By Component, 2023-2033
7.2. Services
7.3. Data Sets
- 7.3.1. Disparate Data Sets
- 7.3.1. Clinical Settings Data
- 7.3.1. Claims Data
- 7.3.1. Pharmacy Data
- 7.3.1. Patient-Powered Data
- 7.3.1. Registry-Based Data Sets
- 7.3.2. Integrated Data Sets

8. Global Real World Evidence Solutions Market, By Application (USD Million)

8.1. Global Real World Evidence Solutions Market Value Share and Forecast, By Application, 2023-2033
8.2. Drug Development and Approvals
- 8.2.1. Oncology
- 8.2.2. Neurology
- 8.2.3. Immunology
- 8.2.4. Cardiovascular Disease
- 8.2.5. Others
- 8.2.6. Medical Device Development and Approvals
8.3. Post-Market Surveillance
8.4. Market Access Reimbursement/Coverage Decision Making
8.5. Clinical and Regulatory Decision-Making

9. Global Real World Evidence Solutions Market, By End User (USD Million)

9.1. Global Real World Evidence Solutions Market Value Share and Forecast, By End User, 2023-2033
9.2. Pharmaceutical & Medical Device Companies
9.3. Healthcare Providers
9.4. Healthcare Payers
9.5. Others

10. Global Real World Evidence Solutions Market Forecast, 2019-2033 (USD Million)

10.1. Global Real World Evidence Solutions Market Size and Market Share

11. Global Real World Evidence Solutions Market, By Component, 2019-2033 (USD Million)

11.1. Global Real World Evidence Solutions Market Size and Market Share By Component (2019-2026)
11.2. Global Real World Evidence Solutions Market Size and Market Share By Component (2027-2033)

12. Global Real World Evidence Solutions Market, By Application, 2019-2033 (USD Million)

12.1. Global Real World Evidence Solutions Market Size and Market Share By Application (2019-2026)
12.2. Global Real World Evidence Solutions Market Size and Market Share By Application (2027-2033)

13. Global Real World Evidence Solutions Market, By End User, 2019-2033 (USD Million)

13.1. Global Real World Evidence Solutions Market Size and Market Share By End User (2019-2026)
13.2. Global Real World Evidence Solutions Market Size and Market Share By End User (2027-2033)

14. Global Real World Evidence Solutions Market, By Region, 2019-2033 (USD Million)

14.1. Global Real World Evidence Solutions Market Size and Market Share By Region (2019-2026)
14.2. Global Real World Evidence Solutions Market Size and Market Share By Region (2027-2033)
14.3. Asia-Pacific
- 14.3.1. Australia
- 14.3.2. China
- 14.3.3. India
- 14.3.4. Japan
- 14.3.5. South Korea
- 14.3.6. Rest of Asia-Pacific
14.4. Europe
- 14.4.1. France
- 14.4.2. Germany
- 14.4.3. Italy
- 14.4.4. Spain
- 14.4.5. United Kingdom
- 14.4.6. Rest of Europe
14.5. Middle East and Africa
- 14.5.1. Kingdom of Saudi Arabia
- 14.5.2. United Arab Emirates
- 14.5.3. Rest of Middle East & Africa
14.6. North America
- 14.6.1. Canada
- 14.6.2. Mexico
- 14.6.3. United States
14.7. Latin America
- 14.7.1. Argentina
- 14.7.2. Brazil
- 14.7.3. Rest of Latin America

15. Company Profile

15.1. IQVIA Holdings
- 15.1.1. Company details
- 15.1.2. Financial outlook
- 15.1.3. Product summary
- 15.1.4. Recent developments
15.2. IBM Corporation
- 15.2.1. Company details
- 15.2.2. Financial outlook
- 15.2.3. Product summary
- 15.2.4. Recent developments
15.3. OPTUM Inc.
- 15.3.1. Company details
- 15.3.2. Financial outlook
- 15.3.3. Product summary
- 15.3.4. Recent developments
15.4. Icon Plc
- 15.4.1. Company details
- 15.4.2. Financial outlook
- 15.4.3. Product summary
- 15.4.4. Recent developments
15.5. Syneous Health Inc.
- 15.5.1. Company details
- 15.5.2. Financial outlook
- 15.5.3. Product summary
- 15.5.4. Recent developments
15.6. Parexel International Corporation
- 15.6.1. Company details
- 15.6.2. Financial outlook
- 15.6.3. Product summary
- 15.6.4. Recent development
15.7. Others